Frontiers in Oncology (Jul 2020)
Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
- Jingpei Li,
- Jingpei Li,
- Jingpei Li,
- Ke Xu,
- Ke Xu,
- Ke Xu,
- Weipeng Cai,
- Weipeng Cai,
- Weipeng Cai,
- Yalei Zhang,
- Yalei Zhang,
- Yalei Zhang,
- Xin Zeng,
- Fei Cui,
- Fei Cui,
- Fei Cui,
- Zhexue Hao,
- Zhexue Hao,
- Zhexue Hao,
- Jun Liu,
- Jun Liu,
- Jun Liu,
- Jianxing He,
- Jianxing He,
- Jianxing He
Affiliations
- Jingpei Li
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Jingpei Li
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Jingpei Li
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Ke Xu
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Ke Xu
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Ke Xu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Weipeng Cai
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Weipeng Cai
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Weipeng Cai
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Yalei Zhang
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Yalei Zhang
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Yalei Zhang
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Xin Zeng
- Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Fei Cui
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Fei Cui
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Fei Cui
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Zhexue Hao
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Zhexue Hao
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Zhexue Hao
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Jun Liu
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Jun Liu
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Jun Liu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- Jianxing He
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Jianxing He
- Guangzhou Institute of Respiratory Health (GIRH), Guangzhou, China
- Jianxing He
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou, China
- DOI
- https://doi.org/10.3389/fonc.2020.01145
- Journal volume & issue
-
Vol. 10
Abstract
We report a case of successful neoadjuvant four-drug combination therapy to avoid total pneumonectomy. A 33-year-old male patient was diagnosed with locally advanced non-squamous NSCLC harboring EGFR mutation in the left lower lobe. The patient experienced significant clinical downstaging after two cycles of neoadjuvant therapy, including icotinib, carboplatin, pemetrexed, and bevacizumab. He underwent a successful lobectomy avoiding pneumonectomy. The patient showed no recurrence in the follow-up of a chest computed tomographic scan, which is 17 months after surgery. The promising results of this neoadjuvant combination therapy provided a novel therapeutic option for patients with locally advanced EGFR-mutated NSCLC facing total pneumonectomy.
Keywords
